Literature DB >> 10824629

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor.

M J Kemme1, J Burggraaf, R C Schoemaker, S Paulson, A Karim, E G Lentjes, A Childs, R A Braeckman, A F Cohen.   

Abstract

OBJECTIVES: Recombinant tissue factor pathway inhibitor (rTFPI) has been shown to be an effective treatment in animal models of sepsis and is under investigation for human use. Reduced liver blood flow during septic shock may substantially alter the pharmacokinetics of rTFPI because clearance of rTFPI approaches liver blood flow. The aim of this study was to examine the effect of exercise-induced reduction in liver blood flow on the pharmacokinetics and pharmacodynamics of rTFPI.
METHODS: This was a two-way, open-label, randomized crossover study in eight healthy male volunteers. The subjects in both treatment groups received a continuous intravenous infusion of rTFPI (0.2 mg/kg/h) concurrently with intravenous sorbitol (50 mg/min) for 4 hours. Sorbitol was used as a biomarker for liver blood flow. The subjects were randomized to remain supine or to exercise on a bicycle ergometer for 30 minutes starting at the beginning of the third hour of the infusion.
RESULTS: Exercise reduced liver blood flow (mean +/- SEM) from 1.44 +/- 0.06 L/min to 0.40 +/- 0.03 L/min. The average clearance of rTFPI decreased from 0.73 +/- 0.04 L/min in the supine position to 0.25 +/- 0.02 L/min during exercise. This decrease in rTFPI clearance resulted in an 80% (95% confidence interval [CI], 60% to 102%) increase in plasma rTFPI levels during exercise. The average maximal prothrombin time and activated partial thromboplastin time values during exercise were 1.4 (95% CI, 0.4 to 2.5) and 4.4 (95% CI, 2.7 to 6.1) seconds higher compared with the supine steady-state level.
CONCLUSIONS: Reduction in liver blood flow by exercise markedly increased rTFPI concentrations and induced a slight but variable prothrombin time and activated partial thromboplastin time increase at the rTFPI dose studied.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824629     DOI: 10.1067/mcp.2000.106796

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

2.  Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139.

Authors:  Feng Shi; Jing Kang Shen; Danqi Chen; Karina Fog; Kenneth Thirstrup; Morten Hentzer; Jens-Jakob Karlsson; Veena Menon; Kenneth A Jones; Kelli E Smith; Garrick Smith
Journal:  ACS Med Chem Lett       Date:  2011-02-28       Impact factor: 4.345

3.  Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients.

Authors:  Mariska Y M Peeters; Leon P H J Aarts; Ferenc A Boom; Leo J Bras; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

4.  Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Authors:  Michiel J B Kemme; Jacobus Burggraaf; Rik C Schoemaker; Cornelis Kluft; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

5.  Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Authors:  Michiel J Kemme; Rik C Schoemaker; Jacobus Burggraaf; Monique van der Linden; Marina Noordzij; Matthijs Moerland; Cornelis Kluft; Adam F Cohen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.